- Home
- ANGO
ANGO
AngioDynamics Inc.
as 12-20-2024 3:30pm EST
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | LATHAM |
| Market Cap: | 279.1M | IPO Year: | 2004 |
| Target Price: | $12.00 | AVG Volume (30 days): | 615.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.26 - $9.58 | Next Earning Date: | 01-08-2025 |
| Revenue: | $292,726,000 | Revenue Growth: | -12.85% |
| Revenue Growth (this year): | -4.73% | Revenue Growth (next year): | 7.69% |
Stock Insider Trading Activity of AngioDynamics Inc. (ANGO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Trowbridge Stephen A | ANGO | EVP and CFO | Oct 8 '24 | Buy | $5.86 | 1,700 | $9,962.00 | 172,711 | |
| Clemmer James C | ANGO | President and CEO | Oct 7 '24 | Buy | $6.03 | 20,000 | $120,600.00 | 681,582 | |
| Nighan Warren JR | ANGO | SVP Quality and Regulatory | Oct 7 '24 | Buy | $6.09 | 868 | $5,285.12 | 45,777 |
Latest AngioDynamics Inc. News
ANGO Breaking Stock News: Dive into ANGO Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
Zacks
12 days ago
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
Zacks
12 days ago
Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?
Medical Device Network
13 days ago
NanoKnife gains FDA clearance for prostate tissue ablation
MT Newswires
13 days ago
AngioDynamics' NanoKnife System Receives FDA Clearance for Prostate Tissue Ablation
Business Wire
13 days ago
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
Zacks
19 days ago
NARI Stock Likely to Gain Following Reimbursement Approval in Japan
Zacks
a month ago
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
Compare ANGO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANGO AngioDynamics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.